Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + Lenvatinib vs Gemox + Lenvatinib in Advanced ICC
NCT04361331Phase 2Completed
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Mar 2020
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of toripalimab in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Objective Response Rate at 12 months. Started Mar 2020; status: completed.
02
Drugs
toripalimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT04361331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04361331.